Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Danaher plans $2.7bn financings to fund concurrent buy of GE Healthcare Life Sciences' biopharma business

Executive Summary

To support its simultaneous proposed acquisition of GE Healthcare Life Sciences' biopharma business for $21.4bn, Danaher Corp. is planning concurrent public offerings for an aggregate $2.7bn ($1.35bn in shares of common stock and $1.35bn in shares of Series A mandatory convertible preferred stock (each share of which is expected to have a liquidation preference of $1k).
Deal Industry
  • In Vitro Diagnostics
  • Medical Devices
  • Research, Analytical Equipment & Supplies
Deal Status
  • Preliminary
Deal Type
  • Financing
    • FOPO

Related Companies